HLOSF
Price
$4.15
Change
+$0.05 (+1.22%)
Updated
Sep 23 closing price
Capitalization
398.72M
SLN
Price
$5.14
Change
-$0.05 (-0.96%)
Updated
Oct 7, 04:58 PM (EDT)
Capitalization
226.72M
42 days until earnings call
Interact to see
Advertisement

HLOSF vs SLN

Header iconHLOSF vs SLN Comparison
Open Charts HLOSF vs SLNBanner chart's image
HEALIOS K K
Price$4.15
Change+$0.05 (+1.22%)
Volume$2.5K
Capitalization398.72M
Silence Therapeutics
Price$5.14
Change-$0.05 (-0.96%)
Volume$400
Capitalization226.72M
HLOSF vs SLN Comparison Chart in %
HLOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HLOSF vs. SLN commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLOSF is a StrongBuy and SLN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (HLOSF: $4.15 vs. SLN: $5.19)
Brand notoriety: HLOSF and SLN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HLOSF: 160% vs. SLN: 38%
Market capitalization -- HLOSF: $398.72M vs. SLN: $226.72M
HLOSF [@Biotechnology] is valued at $398.72M. SLN’s [@Biotechnology] market capitalization is $226.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HLOSF’s FA Score shows that 0 FA rating(s) are green whileSLN’s FA Score has 1 green FA rating(s).

  • HLOSF’s FA Score: 0 green, 5 red.
  • SLN’s FA Score: 1 green, 4 red.
According to our system of comparison, SLN is a better buy in the long-term than HLOSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HLOSF’s TA Score shows that 1 TA indicator(s) are bullish while SLN’s TA Score has 4 bullish TA indicator(s).

  • HLOSF’s TA Score: 1 bullish, 4 bearish.
  • SLN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SLN is a better buy in the short-term than HLOSF.

Price Growth

HLOSF (@Biotechnology) experienced а 0.00% price change this week, while SLN (@Biotechnology) price change was -8.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was +16.24%, and the average quarterly price growth was +90.12%.

Reported Earning Dates

SLN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HLOSF($399M) has a higher market cap than SLN($227M). HLOSF YTD gains are higher at: 207.407 vs. SLN (-24.564). SLN has higher annual earnings (EBITDA): -84.82M vs. HLOSF (-2.39B). HLOSF has more cash in the bank: 6.25B vs. SLN (114M). SLN has less debt than HLOSF: SLN (0) vs HLOSF (2.61B). HLOSF has higher revenues than SLN: HLOSF (112M) vs SLN (27.2M).
HLOSFSLNHLOSF / SLN
Capitalization399M227M176%
EBITDA-2.39B-84.82M2,820%
Gain YTD207.407-24.564-844%
P/E RatioN/AN/A-
Revenue112M27.2M412%
Total Cash6.25B114M5,478%
Total Debt2.61B0-
TECHNICAL ANALYSIS
Technical Analysis
HLOSFSLN
RSI
ODDS (%)
Bearish Trend 2 days ago
33%
Bullish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
15%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
12%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
88%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
33%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
13%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
HLOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TICRX25.12N/A
N/A
Nuveen Large Cap Responsible Eq A
DREQX22.33N/A
N/A
BNY Mellon Research Growth Z
ALABX13.25N/A
N/A
ALPS/Smith Balanced Opportunity A
READX15.60N/A
N/A
Lazard Emerging Markets Eq Advtg R6
FIKJX16.92N/A
N/A
Fidelity Advisor Real Estate Z

HLOSF and

Correlation & Price change

A.I.dvisor tells us that HLOSF and BRTX have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLOSF and BRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLOSF
1D Price
Change %
HLOSF100%
N/A
BRTX - HLOSF
23%
Poorly correlated
+2.00%
LGVN - HLOSF
22%
Poorly correlated
+0.28%
ENTBF - HLOSF
7%
Poorly correlated
N/A
CPMV - HLOSF
5%
Poorly correlated
-41.97%
SLN - HLOSF
3%
Poorly correlated
+3.80%
More

SLN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLN has been loosely correlated with CLLS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLN jumps, then CLLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLN
1D Price
Change %
SLN100%
+3.80%
CLLS - SLN
43%
Loosely correlated
+0.86%
CMVLF - SLN
38%
Loosely correlated
N/A
ANNX - SLN
36%
Loosely correlated
-0.31%
ABCZF - SLN
36%
Loosely correlated
N/A
NGNE - SLN
33%
Loosely correlated
+3.36%
More